SEARCH

SEARCH BY CITATION

References

  • 1
    Miedema HS. Reuma in Nederland: de cijfers. Leiden: TNO Preventie en Gezondheid, 1997.
  • 2
    Schouten JSAG. Artrose. In: MaasIAM, GijsenR, LobbezooIE, PoosMJJC, eds. Volksgezondheid Toekomst Verkenningen 1997. De gezondheidstoestand: een actualisering. Bilthoven: Elsevier/De Tijdstroom, 1997.
  • 3
    Moens HJ, Van Croonenborg JJ, Al MJ, et al. Guideline “NSAID use and the prevention of gastric damage” (in Dutch). Ned Tijdschr Geneeskd 2004; 148:6048.
  • 4
    Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001;19:65565.
  • 5
    Herings RMC, Panneman MJM, Lodder AC, et al. Farmacotherapie in Beweging. Utrecht: PHARMO Instituut, 2000.
  • 6
    Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:19218.
  • 7
    Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in longterm management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:210611.
  • 8
    Burke TA, Zabinski RA, Pettitt D, et al. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001;19(Suppl. 1):S3347.
  • 9
    Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619.
  • 10
    Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998;12:13540.
  • 11
    Ekström P, Carling L, Wetterhus S, et al. Prevention of gastric ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 1996;31:7538.
  • 12
    Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:72734.
  • 13
    Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1993;153:244954.
  • 14
    Rugstad HE, Giercksky KE, Husby G, et al. Effect of cimetidine on gastrointestinal symptoms in patients taking nonsteroidal anti-infammatory drugs. Scand J Rheumatol 1994;23:17782.
  • 15
    Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiiflammatory drugs. N Engl J Med 1996;334:14359.
  • 16
    Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, et al. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: a one-year study. Dig Dis Sci 1995;40:112531.
  • 17
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:2419.
  • 18
    Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:34450.
  • 19
    Roth SH. Misoprostol in the prevention of NSAID-induced gastric ulcer: a multicenter, double-blind, placebo-controlled trial. J Rheumatol 1990;17(Suppl. 20):S2024.
  • 20
    Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:25762.
  • 21
    Elliott SL, Yeomans ND, Buchanan RRC, et al. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. Scand J Rheumatol 1994;23:1716.
  • 22
    Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol 1998;25:160211.
  • 23
    Melo Gomes JA, Roth SH, Bruyn GAW, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993;52:8815.
  • 24
    Verdickt W, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992;21:8591.
  • 25
    Bolten W, Melo Gomes JA, Stead H, et al. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992;31:7538.
  • 26
    Agrawal NM, Caldwell J, Kivitz AJ, et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 1999;21:65974.
  • 27
    Fries JF, Williams CA, Bloch DA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:21322.
  • 28
    Simon LS, Hatoum HT, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Medical 1996;28:20410.
  • 29
    Singh G, Ramey D, Triadafilopoulos G, et al. GI score: a simple self-assessment instrument to quantify the risk of serious NSAID-related complications in RA and OA [abstract]. Arthritis Rheum 1996;39 (Suppl.):S75.
  • 30
    National Institute for Clinical Excellence. Guidance on the Use of Cyclo-Oxygenase (COX) II Selective Inhibitors, Celecoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthitis and Theumatoid Arthritis. London: NHS, 2001.
  • 31
    Fries JF. Assessing and understanding patient risk. Scand J Rheumatol 1992;(Suppl. 92):S214.
  • 32
    Al MJ, Michel BC, Rutten FFH. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics 1996;10:14151.
  • 33
    Ruwaard D, Kramers PGN, eds. Volksgezondheid Toekomst Verkenning 1997: De som de delen. Utrecht: De Tijdstroom, 1997.
  • 34
    Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004. Diemen: College voor Zorgverzekeringen, 2004.
  • 35
    Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985;5:15777.
  • 36
    Van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994;3:30919.
  • 37
    Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:77987.
  • 38
    Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996; 9:11320.
  • 39
    Centraal begeleidingsorgaan voor de Intercollegiale Toetsing. Behandeling en preventie van coronaire hartziekte door verlaging van de plasmacholesterolconcentratie. Utrecht: Centraal begeleidingsorgaan voor de Intercollegiale Toetsing, 1998.
  • 40
    Niessen LW, Dippel DWJ, Limburg M. Berekening van kosten na beroerte en kosteneffectiviteit van “stroke units” en van secundaire preventie, zoals aanbevolen in de herziene CBO-richtlijn “Beroerte”[Calculation of costs and cost-effectiveness of stroke units and of secundary prevention in patients after a stroke, as recommended in the revised CBO guideline “Stroke”]. Ned Tijdschr Geneeskd 2000;144:195964.
  • 41
    Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001;19(Suppl. 1):S4958.
  • 42
    Chancellor JVM, Hunsche E, De Cruz E, et al. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001;19(Suppl. 1):S5975.
  • 43
    Spiegel BM, Targownik L, Dulai GS, et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003;138:795806.
  • 44
    Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003;49:28392.
  • 45
    Yen ZS, Lai MS, Wang CT, et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J Rheumatol 2004;31:1797803.
  • 46
    Haglund U, Svarvar P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford) 2000;39(Suppl. 2): S516.
  • 47
    MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315: 13337.
  • 48
    EMEA. Summary of the product characteristics celebrex 2007. Available from: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=14534[Accessed December 7, 2007].
  • 49
    Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:26674.
  • 50
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:124755.
  • 51
    Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter]. JAMA 2001;286:2398.
  • 52
    Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs? BMJ 2002;324:12878.
  • 53
    Wright JM, Perry TL, Bassett KL, et al. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter]. JAMA 2001;286:239840.
  • 54
    Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003;18:113747.
  • 55
    Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003;42(Suppl. 3):S2331.